Non-Injectable Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Pills, Sprays, and Others), By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores), By Region & Competition, 2021-2031F

January 2026 | 185 pages | ID: N5C40BE8BEAEEN
TechSci Research

Abstracts

The Global Non-Injectable Insulin Market is projected to expand from USD 3.69 Billion in 2025 to USD 6.46 Billion by 2031, registering a CAGR of 9.78%. This market sector focuses on alternative administration routes, including pulmonary inhalation and oral formulations, aimed at delivering insulin without invasive needles. The core catalyst for this growth is the increasing global prevalence of diabetes alongside the urgent necessity to enhance patient adherence among those experiencing needle phobia or injection fatigue. Data from the International Diabetes Federation indicates that approximately 589 million adults worldwide were living with diabetes in 2025, a vast patient population that drives significant demand for convenient therapeutic alternatives capable of overcoming the physical and psychological hurdles of traditional subcutaneous delivery.

Despite the evident benefits for patient quality of life, the market confronts a major obstacle regarding the reduced bioavailability of non-injectable forms compared to standard injectables. This physiological constraint typically requires higher dosage amounts to attain equivalent therapeutic results, which significantly elevates manufacturing expenses and the ultimate cost to the patient. Consequently, strict reimbursement frameworks and the substantial economic burden associated with these treatments serve as primary barriers that could hinder widespread clinical uptake and restrict market growth in regions sensitive to cost.

Market Driver

The primary factor driving the non-injectable insulin industry is the rising global incidence of diabetes mellitus, which intensifies the need to improve patient compliance among those burdened by the psychological and physical aspects of daily injections. This increasing disease prevalence demands scalable, user-friendly therapies that alleviate needle phobia. Projections from the International Diabetes Federation's 'IDF Diabetes Atlas 11th Edition' in 2025 estimate that the adult diabetic population will rise to roughly 853 million by 2050, emphasizing the critical need for alternative delivery systems. The magnitude of this demand is reflected in major pharmaceutical operations; for example, Novo Nordisk reported serving over 45.2 million individuals with serious chronic diseases in 2024, illustrating the massive scale of the patient base awaiting less invasive treatment methods.

Concurrently, the sector is being advanced by increased investment in research and development for alternative insulin formulations. Pharmaceutical companies are aggressively funding innovations in inhaled and oral delivery systems to surmount historical bioavailability issues and enhance therapeutic effectiveness. These financial commitments are essential for moving new technologies from clinical trials to commercial reality. A notable example occurred in February 2025, when Oramed Pharmaceuticals announced a strategic joint venture with a combined capital contribution of $75 million to expedite the development and commercialization of its oral insulin platform. Such significant capital injections confirm the industry's dedication to non-invasive solutions and are projected to fuel the next phase of market expansion by making pain-free insulin administration achievable.

Market Challenge

The principal impediment to the growth of the Global Non-Injectable Insulin Market is the physiological issue of lower bioavailability in pulmonary and oral formulations relative to standard injectables. Since these alternative delivery methods face difficulties in efficiently permeating biological barriers, manufacturers are required to formulate drugs with considerably larger amounts of active insulin to guarantee the patient receives the requisite therapeutic dose. This necessity for increased active pharmaceutical ingredients directly raises production costs, leading to a significantly higher end-price that restricts accessibility for both insurers and patients.

This price disparity creates a major obstacle in regions where healthcare budgets are already under severe strain. Rigid reimbursement policies frequently prioritize lower-cost traditional injectables, leaving costlier non-injectable options without sufficient coverage. The scale of this economic pressure is highlighted by recent statistics on the financial impact of the disease; according to the International Diabetes Federation, global health expenditure due to diabetes reached at least 1 trillion US dollars in 2025. Given these massive existing costs, payers remain hesitant to adopt premium-priced therapies, thereby limiting widespread clinical acceptance and impeding market growth in cost-sensitive areas.

Market Trends

The market is being reshaped by a focus on Ultra-Rapid Acting Inhaled Insulin, which prioritizes formulations that replicate the physiological insulin spike of a healthy pancreas more precisely than traditional subcutaneous injections. This trend emphasizes optimizing the aerodynamic particle size of dry powder formulations to guarantee deep lung deposition and rapid systemic absorption, thereby mitigating the risk of post-prandial hyperglycemia. Manufacturers are effectively converting this pharmacokinetic benefit into commercial success, confirming the demand for rapid-onset non-invasive alternatives. For instance, MannKind Corporation reported in its 'Third Quarter 2024 Financial Results' in November 2024 that Afrezza net revenue rose to $15.0 million, indicating a clear growth trajectory for inhaled therapeutics fueled by rising patient demand and better gross-to-net adjustments.

Concurrently, innovation in Buccal and Sublingual Insulin Sprays is gathering speed as researchers utilize novel peptide carriers to traverse the mucosal barrier without the degradation problems associated with gastrointestinal delivery. This trend focuses on creating liquid formulations administered under the tongue, where high vascularization permits direct entry into the bloodstream, bypassing the hepatic first-pass metabolism that frequently neutralizes oral medications. This technological advancement is directly meeting the needs of substantial national patient populations looking for pain-free options. As noted by the University of British Columbia in the June 2024 article 'UBC-developed oral insulin drops offer relief for diabetes patients,' these new sublingual drops are specifically designed to assist the 11.7 million Canadians living with diabetes or pre-diabetes, underscoring the vast regional market potential for such mucosal delivery innovations.

Key Market Players

• Midatech Pharma Plc
• Shreya Life Sciences Pvt. Ltd.
• Boston Therapeutics, Inc.
• Coromed, Inc.
• Diabetology Ltd.
• Emisphere Technologies, Inc.
• Oramed Pharmaceuticals, Inc.
• Diasome Pharmaceuticals, Inc.
• Generex Biotechnology Corp.
• Biodel, Inc.

Report Scope

In this report, the Global Non-Injectable Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-Injectable Insulin Market, By Product
• Pills
• Sprays
• and Others
• Non-Injectable Insulin Market, By Distribution Channel
• Hospital Pharmacies
• and Online Pharmacies
• Drug Stores
• Non-Injectable Insulin Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.

Available Customizations:

Global Non-Injectable Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL NON-INJECTABLE INSULIN MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Product (Pills, Sprays, and Others)
  5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  5.2.3. By Region
  5.2.4. By Company (2025)
5.3. Market Map

6. NORTH AMERICA NON-INJECTABLE INSULIN MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Product
  6.2.2. By Distribution Channel
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Non-Injectable Insulin Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Product
      6.3.1.2.2. By Distribution Channel
  6.3.2. Canada Non-Injectable Insulin Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Product
      6.3.2.2.2. By Distribution Channel
  6.3.3. Mexico Non-Injectable Insulin Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Product
      6.3.3.2.2. By Distribution Channel

7. EUROPE NON-INJECTABLE INSULIN MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Product
  7.2.2. By Distribution Channel
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Non-Injectable Insulin Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Product
      7.3.1.2.2. By Distribution Channel
  7.3.2. France Non-Injectable Insulin Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Product
      7.3.2.2.2. By Distribution Channel
  7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Product
      7.3.3.2.2. By Distribution Channel
  7.3.4. Italy Non-Injectable Insulin Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Product
      7.3.4.2.2. By Distribution Channel
  7.3.5. Spain Non-Injectable Insulin Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Product
      7.3.5.2.2. By Distribution Channel

8. ASIA PACIFIC NON-INJECTABLE INSULIN MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Product
  8.2.2. By Distribution Channel
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Non-Injectable Insulin Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Product
      8.3.1.2.2. By Distribution Channel
  8.3.2. India Non-Injectable Insulin Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Product
      8.3.2.2.2. By Distribution Channel
  8.3.3. Japan Non-Injectable Insulin Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Product
      8.3.3.2.2. By Distribution Channel
  8.3.4. South Korea Non-Injectable Insulin Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Product
      8.3.4.2.2. By Distribution Channel
  8.3.5. Australia Non-Injectable Insulin Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Product
      8.3.5.2.2. By Distribution Channel

9. MIDDLE EAST & AFRICA NON-INJECTABLE INSULIN MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Product
  9.2.2. By Distribution Channel
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Non-Injectable Insulin Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Product
      9.3.1.2.2. By Distribution Channel
  9.3.2. UAE Non-Injectable Insulin Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Product
      9.3.2.2.2. By Distribution Channel
  9.3.3. South Africa Non-Injectable Insulin Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Product
      9.3.3.2.2. By Distribution Channel

10. SOUTH AMERICA NON-INJECTABLE INSULIN MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Product
  10.2.2. By Distribution Channel
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Non-Injectable Insulin Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Product
      10.3.1.2.2. By Distribution Channel
  10.3.2. Colombia Non-Injectable Insulin Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Product
      10.3.2.2.2. By Distribution Channel
  10.3.3. Argentina Non-Injectable Insulin Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Product
      10.3.3.2.2. By Distribution Channel

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL NON-INJECTABLE INSULIN MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Midatech Pharma Plc
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Shreya Life Sciences Pvt. Ltd.
15.3. Boston Therapeutics, Inc.
15.4. Coromed, Inc.
15.5. Diabetology Ltd.
15.6. Emisphere Technologies, Inc.
15.7. Oramed Pharmaceuticals, Inc.
15.8. Diasome Pharmaceuticals, Inc.
15.9. Generex Biotechnology Corp.
15.10. Biodel, Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER